
Regional Monitoring EECA
by ECUO PLWH

# | Country | Source of financing | Manufacturer | Tradename | INN | Form | Price per unit ($) | Units in purchase | Units in package | Price per package ($) | Packages in purchase | Price per purchase ($) | Distributor | Year | Purchase date | Delivery date | Registered | In the list of main (vital) medications | WHO prequalification |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Republic of Poland | Government | Gilead Sciences | Atripla | Efavirenz+Emtricitabin+Tenofovir Disoproxil | 600mg+200mg+245mg tab | 26.436 | 9000 | 30 | 793.08 | 300 | 237924 | 2015 | Not specified | Not specified | Not specified | |||
2 | Republic of Poland | Government | Gilead Sciences | Atripla | Efavirenz+Emtricitabin+Tenofovir Disoproxil | 600mg+200mg+245mg tab | 26.436 | 6000 | 30 | 793.08 | 200 | 158616 | 2015 | Not specified | Not specified | Not specified |